December 28, 2017 — Zoll Medical Corp. and Myant, Inc., a high-tech advanced manufacturing company, announced they have entered an exclusive strategic multi-year agreement to jointly develop technologies that will be leveraged in future generations of the Zoll LifeVest wearable defibrillator. The LifeVest is worn by patients at risk of sudden cardiac death (SCD), providing protection during their changing condition and while permanent SCD risk has not been established.
The LifeVest was approved by the U.S. Food and Drug Administration (FDA) in 2001. Recommended use of the wearable defibrillator is included in the 2017 American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society (HRS) Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
The LifeVest is used for a wide range of patient conditions or situations, including following a myocardial infarction, before or after coronary revascularization, and for those with cardiomyopathy or congestive heart failure that places them at particular risk. The technology allows patients to return to their common activities of daily living, while having the peace of mind that they are protected from SCD. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.
Myant focuses on advancing human connectedness to the Internet of Things by designing, developing and producing connected textile-based products.
Read the article "Zoll LifeVest Shows 97 Percent One-Year Survival for High-Risk Patients"
For more information: www.zoll.com
January 14, 2026 
